LobbyingVerily Life Sciences lobbying by quarter
Verily Life Sciences's latest lobbying report covers Q2 2026, at under $5,000. The four quarters Q4 2025–Q3 2026 total $20K. Its first report covers Q3 2023; the issues it reports most are Health Issues and Medical/Disease Research/Clinical Labs.
Verily Life Sciences
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $20K
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q3 2023
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q3 2023 | $0 | 1 |
| Q4 2023 | $0 | 1 |
| Q1 2024 | $0 | 1 |
| Q2 2024 | $0 | 1 |
| Q3 2024 | $0 | 1 |
| Q4 2024 | $0 | 1 |
| Q1 2025 | $10K | 1 |
| Q2 2025 | $10K | 1 |
| Q3 2025 | $10K | 1 |
| Q4 2025 | $10K | 1 |
| Q1 2026 | $10K | 1 |
| Q2 2026 | $0 | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$16.7K · 12 reports
- Medical research and clinical labs$16.7K · 12 reports
- Medicare and Medicaid$16.7K · 12 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- Defense, Dept of (DOD)12 reports
- HOUSE OF REPRESENTATIVES12 reports
- SENATE12 reports
Firms it paid
| Firm | ||
|---|---|---|
| McDermott+ | $50K | 12 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| JULIA GRABO | 2021: Paid Intern, Rep. Colin Allred | Q2 2026 |
| RACHEL STAUFFER | 2013-2015: Health Policy Director, Rep. Diana DeGette; 2008-2011: Legislative Assistant, Senior Legislative Assistant, Rep. John Tierney | Q2 2026 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/06for Q2 | McDermott+ | Under $5,000 |
| 03/31for Q1 | McDermott+ | $10K |
| 01/05for Q4 2025 | McDermott+ | $10K |
| 25/10/08for Q3 2025 | McDermott+ | $10K |
| 25/07/01for Q2 2025 | McDermott+ | $10K |
| 25/04/03for Q1 2025 | McDermott+ | $10K |
| 25/01/15for Q4 2024 | McDermott+ | Under $5,000 |
| 24/10/14for Q3 2024 | McDermott+ | Under $5,000 |
| 24/06/26for Q2 2024 | McDermott+ | Under $5,000 |
| 24/04/08for Q1 2024 | McDermott+ | Under $5,000 |
| 24/01/03for Q4 2023 | McDermott+ | Under $5,000 |
| 23/10/16for Q3 2023 | McDermott+ | Under $5,000 |
| 23/08/30for Q3 2023 | McDermott+ | Under $5,000 |